Derphartox

Derphartox was a specialized preclinical contract research organization (CRO) based in the Netherlands that focused on dermatological drug research and toxicology. Founded in 2001, the company utilized advanced human skin models, including in vitro and humanized in vivo systems, to evaluate the safety and efficacy of topical treatments. Derphartox was notably involved in research regarding the inhibition of fatty acid oxidation for the treatment of psoriasis, collaborating with partners like Medigene AG on the development of the CPT-1 inhibitor Etomoxir. The company provided specialized services for assessing skin irritancy and sensitization potential, supporting the early-stage development of dermatological therapies. Although it was a key player in the Leiden Bio Science Park cluster, the company is currently inactive.